Detalles de la búsqueda
1.
Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11.
J Med Chem
; 48(7): 2258-61, 2005 Apr 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-15801816
2.
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
J Med Chem
; 48(18): 5639-43, 2005 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-16134929
3.
Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model.
J Med Chem
; 47(7): 1609-12, 2004 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-15027851
4.
Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R).
Bioorg Med Chem Lett
; 17(8): 2317-21, 2007 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17317169
5.
Novel 1H-(benzimidazol-2-yl)-1H-pyridin-2-one inhibitors of insulin-like growth factor I (IGF-1R) kinase.
Bioorg Med Chem Lett
; 17(4): 974-7, 2007 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17187980
Resultados
1 -
5
de 5
1
Próxima >
>>